Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Deepika Radhakrishnan, Vaishwik Patel, Shan Mohanan, Sharon Wong, Jacob Netherton, Ajay Karakoti & Ajayan Vinu. (2023) Combinatorial treatment using bevacizumab/pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer. Science and Technology of Advanced Materials 24:1.
Read now
Read now
Huseyin Akilli, Samed Rahatli, Khayala Aliyeva, Ozden Altundag, Ulku Esra Kuscu & Ali Ayhan. (2022) Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study. Journal of Obstetrics and Gynaecology 42:6, pages 2230-2234.
Read now
Read now
Haiyong Wang, Hui Zhu, Li Kong & Jinming Yu. (2016) Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. OncoTargets and Therapy 9, pages 4639-4644.
Read now
Read now
Rima Ait-Belkacem, Caroline Berenguer, Claude Villard, L’Houcine Ouafik, Dominique Figarella-Branger, Alain Beck, Olivier Chinot & Daniel Lafitte. (2014) Monitoring therapeutic monoclonal antibodies in brain tumor. mAbs 6:6, pages 1385-1393.
Read now
Read now
Judy W King & Siow-Ming Lee. (2013)
Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Investigational Drugs 22:6, pages 765-773.
Read now
Read now
Ashesh A. Thaker, Faezeh Razjouyan, David L. Woods, Dieter Haemmerich, Kiran Sekhar, Bradford J. Wood & Matthew R. Dreher. (2012) Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma. International Journal of Hyperthermia 28:8, pages 766-775.
Read now
Read now
Charu Aggarwal, Neeta Somaiah & George Simon. (2012) Antiangiogenic agents in the management of non-small cell lung cancer. Cancer Biology & Therapy 13:5, pages 247-263.
Read now
Read now
Katie E Lacy, Sophia N Karagiannis & Frank O Nestle. (2012) Immunotherapy for melanoma. Expert Review of Dermatology 7:1, pages 51-68.
Read now
Read now
Susanna V. Ulahannan & Julie R. Brahmer. (2011) Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation 29:4, pages 325-337.
Read now
Read now
Articles from other publishers (45)
Jun Gong, Juanjuan Gu, Lili Jiang, Dongxia Zhao, Lili Shao, Xi Chen & Jianhua Liu. (2022) Clinical Study on the Efficacy of Bevacizumab in Combination with Pembrolizumab on Cellular Immune Function in the Treatment of Driver Gene-Negative Stage IV Lung Adenocarcinoma. Journal of Oncology 2022, pages 1-8.
Crossref
Crossref
Marion Ferreira, Thomas Secher, Nathalie Heuze-Vourc’H & Karen L Reckamp. (2021) Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics 13:6, pages 912.
Crossref
Crossref
Jiaying Wang, Conghui Wang, Yang Li, Mingyue Li, Tingjia Zhu, Zhangjin Shen, Hui Wang, Weiguo Lv, Xinyu Wang, Xiaodong Cheng & Xing Xie. (2021) Potential of peptide‐engineered exosomes with overexpressed miR‐92b‐3p in anti‐angiogenic therapy of ovarian cancer. Clinical and Translational Medicine 11:5.
Crossref
Crossref
Taranom Mobasheri, Elham Rayzan, Mahsima Shabani, Mina Hosseini, Ghanbar Mahmoodi Chalbatani & Nima Rezaei. (2020) Neuroblastoma‐targeted nanoparticles and novel nanotechnology‐based treatment methods. Journal of Cellular Physiology 236:3, pages 1751-1775.
Crossref
Crossref
Eliot R. Dow, Jennifer O. Adeghate, Peter G. Coombs, Mrinali Gupta Patel, Donald J. D’Amico & Szilárd Kiss. (2019) Fellow-Eye Conversion and Treatment in Exudative Age-Related Macular Degeneration. Journal of VitreoRetinal Diseases 3:6, pages 438-444.
Crossref
Crossref
Zhichao Liu, Youting Bao, Butuo Li, Xindong Sun & Linlin Wang. (2018) Does ALK‐rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non‐small‐cell lung cancer? Case report and literature review. Clinical and Translational Medicine 7:1.
Crossref
Crossref
Daniel S. Chen & Herbert Hurwitz. (2018) Combinations of Bevacizumab With Cancer Immunotherapy. The Cancer Journal 24:4, pages 193-204.
Crossref
Crossref
Nasha Zhang, Li Kong, Fang Shi, Wang Jing, Haiyong Wang, Ming Yang, Jinming Yu & Hui Zhu. (2017) Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed. Oncotarget 8:43, pages 74910-74916.
Crossref
Crossref
Yuting Zhan, Hongjing Zang, Juan Feng, Junmi Lu, Lingjiao Chen & Songqing Fan. (2017) Long non-coding RNAs associated with non-small cell lung cancer. Oncotarget 8:40, pages 69174-69184.
Crossref
Crossref
Mark A. Socinski, Jamie E. Chaft, Benjamin Levy, Gregory J. Riely, Corey J. Langer, Roman Perez-Soler, Deborah L. Middleton, Linda Gracie-King & Laura M. Healy. (2017) The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. Clinical Lung Cancer 18:3, pages 255-258.
Crossref
Crossref
Angela Musella, Laura Vertechy, Alessia Romito, Claudia Marchetti, Andrea Giannini, Valentina Sciuga, Carlotta Bracchi, Federica Tomao, Violante Di Donato, Francesca De Felice, Marco Monti, Ludovico Muzii & Pierluigi Benedetti Panici. (2017) Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions. Chemotherapy 62:2, pages 111-120.
Crossref
Crossref
A. Argiris, J.E. Bauman, J. Ohr, W.E. Gooding, D.E. Heron, U. Duvvuri, G.J. Kubicek, D.M. Posluszny, M. Vassilakopoulou, S. Kim, J.R. Grandis, J.T. Johnson, M.K. Gibson, D.A. Clump, J.T. Flaherty, S.I. Chiosea, B. Branstetter & R.L. Ferris. (2016) Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Annals of Oncology 27:8, pages 1594-1600.
Crossref
Crossref
Dimitri PsimarasCamille TafaniFrancois DucrayDelphine LeclercqLoic FeuvretJean Yves DelattreDamien Ricard. (2016) Bevacizumab in late-onset radiation-induced myelopathy. Neurology 86:5, pages 454-457.
Crossref
Crossref
Maximilian Niyazi, Patrick N. Harter, Elke Hattingen, Maya Rottler, Louisa von Baumgarten, Martin Proescholdt, Claus Belka, Kirsten Lauber & Michel Mittelbronn. (2015) Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?. Oncotarget 7:3, pages 2313-2328.
Crossref
Crossref
真真 王. (2016) Analysis of Prognostic Factors in 168 Cases of Lung Adenocarcinoma Patients Treated with Targeted Therapy Combined with Chemotherapy. Asian Case Reports in Oncology 05:01, pages 1-13.
Crossref
Crossref
Edward M. BarksdaleJr.Jr. & Iuliana D. Bobanga. 2016. The Surgery of Childhood Tumors. The Surgery of Childhood Tumors
681
710
.
Ke-Jun Liu & Hai-Ying Wu. (2015) A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. Oncotarget 6:26, pages 22750-22757.
Crossref
Crossref
SHUJI KUBO, MISATO TAKAGI-KIMURA & NORIYUKI KASAHARA. (2015) Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model. Oncology Reports 34:2, pages 633-638.
Crossref
Crossref
Geoffrey Pomme, Florian Augustin, Michael Fiegl, Raoul A. Droeser, William Sterlacci & Alexandar Tzankov. (2015) Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics. Virchows Archiv 467:1, pages 55-66.
Crossref
Crossref
Ke-jun Liu, Ling-yu Ding & Hai-ying Wu. (2015) Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer. Tumor Biology 36:3, pages 1323-1327.
Crossref
Crossref
M J Hicks, K Funato, L Wang, E Aronowitz, J P Dyke, D J Ballon, D F Havlicek, E Z Frenk, B P De, M J Chiuchiolo, D Sondhi, N R Hackett, S M Kaminsky, V Tabar & R G Crystal. (2014) Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Therapy 22:1, pages 1-8.
Crossref
Crossref
Maximilian Niyazi, Nathalie Lisa Jansen, Maya Rottler, Ute Ganswindt & Claus Belka. (2014) Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiation Oncology 9:1.
Crossref
Crossref
Maximilian Niyazi, Maya Flieger, Ute Ganswindt, Stephanie E Combs & Claus Belka. (2014) Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort. Radiation Oncology 9:1.
Crossref
Crossref
Jing-Tao Zhang, Wei Sun, Wen-Zhong Zhang, Chun-Yan Ge, Zhong-Yan Liu, Ze-Ming Zhao, Xing-Sui Lu & Yue-Zu Fan. (2014) Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway. BMC Cancer 14:1.
Crossref
Crossref
Maya Flieger, Ute Ganswindt, Silke Birgit Schwarz, Friedrich-Wilhelm Kreth, J?rg-Christian Tonn, Christian la Foug?re, Lorenz Ertl, Jennifer Linn, Ulrich Herrlinger, Claus Belka & Maximilian Niyazi. (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. Journal of Neuro-Oncology 117:2, pages 337-345.
Crossref
Crossref
Ketan Sharma & Jeffrey R. Marcus. (2013) Bevacizumab and Wound-Healing Complications. Annals of Plastic Surgery 71:4, pages 434-440.
Crossref
Crossref
Wei Luo, Qiang Hu, Dan Wang, Kristin K. Deeb, Yingyu Ma, Carl D. Morrison, Song Liu, Candace S. Johnson & Donald L. Trump. (2013) Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue. Oncotarget 4:9, pages 1472-1483.
Crossref
Crossref
Gunnar Hedlund, Göran Forsberg, Thore Nederman, Anette Sundstedt, Leif Dahlberg, Mikael Tiensuu & Mats Nilsson. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals
365
381
.
Jasmin Pansy, Peter Fritsch, Petra Sovinz, Herwig Lackner, Wolfgang Schwinger, Christian Urban & Martin Benesch. (2013) Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors. Anti-Cancer Drugs 24:2, pages 198-203.
Crossref
Crossref
Daniel Spira, Helge Neumeister, Sven Michael Spira, J?rgen Hetzel, Werner Spengler, Claus Hann von Weyhern & Marius Horger. (2013) Assessment of Tumor Vascularity in Lung Cancer Using Volume Perfusion CT (VPCT) With Histopathologic Comparison. Journal of Computer Assisted Tomography 37:1, pages 15-21.
Crossref
Crossref
A. Argiris, A.P. Kotsakis, T. Hoang, F.P. Worden, P. Savvides, M.K. Gibson, R. Gyanchandani, G.R. BlumenscheinJr.Jr., H.X. Chen, J.R. Grandis, P.M. Harari, M.S. Kies & S. Kim. (2013) Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology 24:1, pages 220-225.
Crossref
Crossref
Atil Bisgin, Aysegul Kargi, Arzu D Yalcin, Cigdem Aydin, Deniz Ekinci, Burhan Savas & Salih Sanlioglu. (2012) Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 12:1.
Crossref
Crossref
Cynthia E. Weber & Paul C. Kuo. (2012) The tumor microenvironment. Surgical Oncology 21:3, pages 172-177.
Crossref
Crossref
Shahe Boghossian, Stuart Robinson, Alexei Von Delwig, Derek Manas & Steve White. (2012) Immunotherapy for treating metastatic colorectal cancer. Surgical Oncology 21:2, pages 67-77.
Crossref
Crossref
Terence F. McGuire, Gangadharan B. Sajithlal, Jie Lu, Robert D. Nicholls & Edward V. Prochownik. (2012) In Vivo Evolution of Tumor-Derived Endothelial Cells. PLoS ONE 7:5, pages e37138.
Crossref
Crossref
Maximilian Niyazi, Ute Ganswindt, Silke Birgit Schwarz, Friedrich-Wilhelm Kreth, Jörg-Christian Tonn, Julia Geisler, Christian la Fougère, Lorenz Ertl, Jennifer Linn, Axel Siefert & Claus Belka. (2012) Irradiation and Bevacizumab in High-Grade Glioma Retreatment Settings. International Journal of Radiation Oncology*Biology*Physics 82:1, pages 67-76.
Crossref
Crossref
Friedemann Kiefer & Arndt F. Siekmann. (2011) The role of chemokines and their receptors in angiogenesis. Cellular and Molecular Life Sciences 68:17, pages 2811-2830.
Crossref
Crossref
George Somlo, Ashkan Lashkari, William Bellamy, Todd M. Zimmerman, Joseph M. Tuscano, Margaret R. O?Donnell, Ann F. Mohrbacher, Stephen J. Forman, Paul Frankel, Helen X. Chen, James H. Doroshow & David R. Gandara. (2011) Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. British Journal of Haematology 154:4, pages 533-535.
Crossref
Crossref
S. Grau, J. Thorsteinsdottir, L. von Baumgarten, F. Winkler, J.-C. Tonn & C. Schichor. (2011) Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. Journal of Neuro-Oncology 104:1, pages 103-112.
Crossref
Crossref
Weijing Sun, Davendra Sohal, Daniel G. Haller, Kristine Mykulowycz, Mark Rosen, Michael C. Soulen, Millie Caparro, Ursina R. Teitelbaum, Bruce Giantonio, Peter J. O'Dwyer, Abraham Shaked, Rajender Reddy & Kim Olthoff. (2011) Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117:14, pages 3187-3192.
Crossref
Crossref
Stephen H. Wrzesinski, Tamar H. Taddei & Mario Strazzabosco. (2011) Systemic Therapy in Hepatocellular Carcinoma. Clinics in Liver Disease 15:2, pages 423-441.
Crossref
Crossref
Athanassios ArgirisMichalis V. KaramouzisWilliam E. GoodingBarton F. BranstetterShilong ZhongLuis E. RaezPanayiotis SavvidesMarjorie Romkes. (2011) Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal of Clinical Oncology 29:9, pages 1140-1145.
Crossref
Crossref
Joseph P. Erinjeri, Abigail J. Fong, Nancy E. Kemeny, Karen T. Brown, George I. Getrajdman & Stephen B. Solomon. (2010) Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 117:6, pages 1296-1301.
Crossref
Crossref
Jan W. Gratama, Cor H. J. Lamers & Reno Debets. 2011. Principles of Immunopharmacology. Principles of Immunopharmacology
151
178
.
Anil Bagri, Hosein Kouros-Mehr, Kevin G. Leong & Greg D. Plowman. (2010) Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends in Molecular Medicine 16:3, pages 122-132.
Crossref
Crossref